Capital Investment Services of America Inc. Boosts Stake in IDEXX Laboratories, Inc. $IDXX

Capital Investment Services of America Inc. increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 39,862 shares of the company’s stock after acquiring an additional 328 shares during the period. IDEXX Laboratories makes up about 2.0% of Capital Investment Services of America Inc.’s portfolio, making the stock its 26th largest holding. Capital Investment Services of America Inc.’s holdings in IDEXX Laboratories were worth $21,380,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. MorganRosel Wealth Management LLC acquired a new stake in IDEXX Laboratories in the first quarter valued at approximately $26,000. Opal Wealth Advisors LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. grew its stake in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after acquiring an additional 30 shares during the period. Ameritas Advisory Services LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth $36,000. Finally, WPG Advisers LLC purchased a new position in IDEXX Laboratories during the first quarter valued at $37,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on IDXX shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. UBS Group started coverage on shares of IDEXX Laboratories in a research report on Wednesday, October 1st. They set a “neutral” rating and a $720.00 price target for the company. Leerink Partners upped their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. BTIG Research increased their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Finally, Morgan Stanley boosted their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $656.50.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Sharon E. Underberg sold 5,450 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the sale, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. This trade represents a 46.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Nimrata Hunt sold 1,200 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $656.53, for a total value of $787,836.00. Following the transaction, the executive vice president directly owned 16,807 shares of the company’s stock, valued at approximately $11,034,299.71. This represents a 6.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock valued at $34,293,468 over the last quarter. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Down 0.5%

Shares of NASDAQ IDXX opened at $633.78 on Thursday. The stock has a market cap of $50.70 billion, a P/E ratio of 52.77, a PEG ratio of 4.12 and a beta of 1.58. The business’s fifty day simple moving average is $638.91 and its 200-day simple moving average is $554.07. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.